



Title: **Sample Humanitarian Use Device (HUD)**

General Information

1 * **Protocol Title:**

Sample Humanitarian Use Device (HUD)

Maximum of 230 characters may be entered.

2 **Full Title - If protocol title exceeds the 230 characters limited from field above, enter full title here. Otherwise, leave blank.**

Sample Humanitarian Use Device (HUD)

3 * **Provide a brief summary (in lay terms) of the research protocol.**

Brief summary

4 * **Principal Investigator (PI):** [PI Test](#)

4.1 * **To serve as a PI you must qualify under one of the following eligibility requirements. (Residents, interns, fellows and postdoctoral candidates are not permitted to be PIs). Please select the appropriate category that applies to you.**

Physicians, Dentists and Psychologists credentialed through the hospital with the BCH medical staff registrar as an active medical staff member and having an appointment of Instructor or higher at Harvard Medical School.

If Other patient services professionals:

4.1.1 **Research is part of your scope of employment responsibility and not to meet a training or degree requirement. Please explain how this research falls within the scope of your responsibilities at the hospital.**

4.1.2 **You have training and experience and confirmed clinical research competencies. Please explain your training and experience in clinical research.**

4.1.3 **Are you employed at Children's as a nurse or do you have nursing credentials through Boston Children's Hospital? Please note if this is checked yes, in accordance with the policies of the Nursing Department your protocol will be sent to the Nursing department for both scientific review and departmental sign off.**

Yes No

5 * **Is the person who will be primarily responsible for conducting the study at BCH different from the PI?**

Yes No

If YES:

5.1 **Please add the person(s) who will be primarily responsible for conducting the study.**

Name	Appointment with Children's Hospital?
------	---------------------------------------

There are no items to display

6 **Has the PI, or if question #5 was YES has that person, previously served as a PI of a protocol involving interaction/intervention with human subjects at CHB?**

Yes No

7 * **Type Of Submission:**

- New Research Activity
- **New Research Activity Limited to Secondary* Use of Biological Material and Data
- Establishment of Human Biological Specimen Repository/ Data Registry (only) – repositories/registries are defined as a prospective collections of specimens or data that are processed, stored, distributed to multiple investigators for use in research.
- Request for Exemption
- Individual Patient Expanded Access
- Humanitarian Use Device (HUD)**
- Reliance on Another IRB
- Projects that lack immediate plans for involvement with human subjects, their data and/or their specimens (i.e.training grants)

** Use this form only if:

- 1) specimens/data are not identifiable or
- 2) specimens/data are identifiable but recorded by PI in de-identified format or meet the waiver of HIPAA authorization criteria listed below All other uses of secondary specimens/data must be submitted on a new research activity form.

* Secondary means the tissue or data will be or was collected for a primary or initial purpose other than the research (i.e data from medical records, tissue from pathology)

Waiver of HIPAA authorization (all criteria must be met)

- The proposed use of this data/document/record/specimen presents no more than minimal risk to the privacy of individuals
- The research could not practicably be conducted without the waiver of HIPAA authorization
- The research could not practicably be conducted without access to and use of protected health information with identifiers
- Waiving HIPAA authorization will not adversely affect the subject's rights or welfare

This form may not be selected if the study involves interaction/intervention with subjects in order to obtain tissue/data specifically for this research.

8 * Is this protocol related to child health (including perinatology, prenatal assessments, childhood antecedents of adult disease, and long-term follow up of pediatric disorders)?

- Yes No

9 * Is this protocol related to cancer (primarily concerning malignancies, oncology patients, or involving use of malignant tumors)?

- Yes No

Note: If YES, your protocol will require review by the Dana Farber IRB instead.

For details, see: [IRB Policy 3.12, 'Reliance Agreements'](#)

10 * Will this protocol utilize any of the services of the ETU (Experimental Therapeutics Unit)?

Please select "No" for the following types of submission:

1. Request for Exemption
2. Projects that lack immediate plans for involvement with human subjects, their data and/or their specimens (i.e.training grants)

- Yes No

These services include:

- Use of space on the ETU or research space at Waltham
- Nursing assistance at above sites
- Off-site nursing and/or research coordinator services provided through ETU
- Specimen collection or processing, sample storage and preparation for shipping
- Assistance from nutritional Metabolic Phenotyping Core (preparation of research meals, analysis of food records, etc.)
- Use of specialist equipment located on the ETU (3DMD camera, DXA, pQCT, V-max, etc.)

Note: If YES, your protocol will be routed for Harvard Catalyst CRC Protocol Review PRIOR to BCH IRB

review. For details, see: *Institutional Centers for Clinical and Translational Research (ICCTR)*

- 11 * Does this protocol include COVID-related research with subjects diagnosed or suspected with COVID19 that meet any of the following criteria?
- Use of discard clinical samples (nasal swabs, blood, etc.)
 - Collection of clinical samples from patients (blood, nasal swabs, sputum, urine, stool etc.)
 - Collection of demographic and clinical information at time of patient encounter
 - Interaction or intervention with patients (therapies, extra testing , interviews) while in the hospital (inpatient, ambulatory, emergency department)
- Yes No

Note: Do not check "Yes" for research limited to retrospective or prospective collection of data or surveys/interviews conducted with families and patients through non inperson encounters.

Note: If "Yes" - the scientific review will be automatically routed to a newly formed SRC committee established to conduct COVID19 research reviews. In addition you are required to obtain approval by institutional representatives who have been assigned responsibility by hospital location for prioritizing multiple requests, assuring protocols meet standards for infection control, and appropriate personnel are involved. Please contact them early during your research planning so they can provide guidance. Please note that the processes, capabilities, and requirements differ by site.

Investigators with proposals than span different locations should discuss their research plan with all site leads:
 ED: Mark Neuman, MD
 ICU and ORs: Adrienne Randolph, MD
 In-patient: Benji Raby, MD
 Laboratory Medicine: Orah Platt, MD and Nira Pollock, MD

If you would like to request ICCTR support please contact Andy Place, MD (Chief Medical Officer) and Cindy Williams, RN MS, NE-BC (nursing)

Research Team

If the person you need to add to your protocol cannot be found using the "Add" buttons below, please send an email to CHERP Support (cherp.support@childrens.harvard.edu) requesting that the person be added to the Research Staff. CHERP Support will need the following information:

- First Name
- Last Name
- CHID# (if applicable)
- BCH Department (if applicable)
- Email Address

1 Research Staff - Children's Hospital Employees only:

	Last Name	First Name	Role	Editor	CC on Correspondence	Required Training Completed	CHERP Training	Date Modified	Date Created
View	Kuniholm	Ashley	Admin Contact	yes	yes	yes	yes	12/4/2019	12/4/2019

2 **NOTE: Accounts are no longer required for non-BCH researchers. These individuals remain under the jurisdiction of their home institution's IRB and should not be listed here. If you think there is a special circumstance, please contact your IRB Administrator.**

Research Staff - Non Children's Hospital Employees only:

Last Name	First Name	Role	Email	Required Training Completed
There are no items to display				

3 PI: PI Test

Completed Training Courses:

Training Program	Continuing Education Description	Training Completed	Date Created
Continuing Education	Collaborative IRB Training Initiative (CITI Continuing Education)	7/22/2018	
Continuing Education	Collaborative IRB Training Initiative (CITI Continuing Education)	7/12/2018	
Continuing Education	Continuing Education/Department Meeting	5/2/2018	
Continuing Education	Continuing Education/Department Meeting	6/13/2016	
Training Received at Another Institution		11/15/2015	
Continuing Education	Continuing Education/Department Meeting	10/26/2015	
Continuing Education	Research Protocol Case Discussions	11/15/2012	
Continuing Education	Collaborative IRB Training Initiative (CITI Continuing Education)	5/9/2012	5/9/2012
Continuing Education	Continuing Education/Department Meeting	9/30/2011	
CHERP Training		12/19/2010	
Continuing Education	Collaborative IRB Training Initiative (CITI Continuing Education)	5/15/2009	11/8/2010
Collaborative IRB Training Initiative (CITI Behavioral)		8/2/2006	11/8/2010
Collaborative IRB Training Initiative (CITI Biomedical)		8/2/2006	11/8/2010
Collaborative IRB Training Initiative (CITI Non-Interventional)		4/11/2006	11/8/2010
Continuing Education	Collaborative IRB Training Initiative (CITI Continuing Education)	4/5/2006	11/8/2010

Title: Sample Humanitarian Use Device (HUD)

Funding Sources

1 * Select funding category.

- Externally sponsored (federal, state, corporate, foundations)
- Internally sponsored
- Externally and internally sponsored
- No sponsor
- Private Donor**

1.1 If internally sponsored - select as appropriate:

- Department/ Division or Children's foundation funds
- Internal Children's Grant Award

1.2 Enter any additional information if applicable:

1.3 If the protocol does not have a sponsor, please detail how the study will be conducted without funding.

1.4 Please provide the name of the private donor.
Private donor

Financial Disclosure

- 1 * Do you or any person affiliated with the protocol have or expect to have any investment or financial relationship (examples below) with any entity that is providing funds or other support in connection with the protocol?

Yes No

If YES:

1.1 Please select the relationships as appropriate.

- Consulting
- Payments for protocol/study design
- Protocol-related payments not included in the research agreement budget
- Stock or Options
- Honoraria
- Scientific Advisory Board Membership
- Royalties or license fees related to the protocol, or to any test article or device which will be employed in the conduct of the research under the protocol (including any royalties or license fees received through an academic institution, including Children's Hospital).
- Equipment or other laboratory support
- Other support for research unrelated to the protocol
- Support for educational or other academic or medical efforts
- Other Grants
- Other

- 2 * Do you or any person affiliated with the protocol have or expect to have any proprietary interest related to the protocol, or related to any test article or device that will be employed in the protocol? Include proprietary interests that you have assigned to any entity, including any institution you have been affiliated with.

Yes No

If YES:

2.1 Please select the proprietary interest as appropriate.

- Patent-licensed, in whole or part, to an entity providing funds for the research
- Patent-licensed, in whole or part, to another entity
- Other

- 3 * Do you or any person affiliated with the protocol have or expect to have any advisory role, appointment, or employment with any entity that is providing funds or other support for the research to be conducted under the protocol?

Yes No

If YES:

3.1 Please select as appropriate.

- Scientific Advisory Board Membership
- Other Advisory Role
- Officer
- Director
- Employment

Other

4 * Do you or any person affiliated with the protocol have or expect to have any financial interest, financial relationship, or position or advisory role with any other entity that may be affected by the research to be conducted under the protocol (e.g. competitor, customer, collaborator or commercial sponsor affiliate)? Include any entity that may be benefited or harmed, directly or indirectly.

Yes No

5 * Do you or any person affiliated with the protocol have or know of any arrangement or understanding, tentative or final, relating to any future financial interest, financial relationship, future grant, position, or advisory role either related to the protocol, or dependent on the outcome of the research under the protocol?

Yes No

6 * The IRB prohibits special incentives in connection with clinical research, including, finder's fees, referral fees, recruitment bonuses, enrollment bonuses for reaching an accrual goal, or similar types of payments. Will you or anyone else in connection with the conduct of any research under the protocol receive money, gifts or anything of monetary value that is above and beyond the actual costs of enrollment, research conduct, and reporting of results, from the sponsor or any other entity?

Yes No

7 * Is there anything not disclosed above which you believe might constitute a conflict of interest or an appearance of a conflict of interest in connection with the protocol?

Yes No

8 If any of the questions above are checked "Yes", please provide the name of the individual for whom the disclosure is made and describe in further details the disclosure. This section must include a full description of the financial relationship, including but not limited to, a detailed description, as applicable, of any test article or device involved; the advisory role or appointment; the competitor, customer, collaborator; any arrangement related to the research; and so on. Please also include actual amounts of any consulting or other monies received and the time period for which it was received. This section will not be reviewed without a full disclosure.

9 Upload any other pertinent documentation.

Name	Date Last Modified	Version	Owner
------	--------------------	---------	-------

There are no items to display

Humanitarian Use Device

1 * Name of Humanitarian Use Device (please include the generic and trade names as applicable)
Humanitarian Use Device

2 * Source (supplier or manufacturer) of the device
Device Manufacturer

3 Date of HUD designation, if known.

4 * FDA assigned HDE number

- 5 * **What are the indications for the use of the device(disease or condition that the device is intended to treat or diagnose)?**
Indications for use

- 6 * **Provide a brief description of the device.**
Description of device

- 7 * **What is the age range of the subjects?**
Age range

- 8 * **Describe the contraindications, warnings and precautions for use of the device.**
Contraindications

- 9 * **Are there any alternative practices, procedures or devices available to treat or diagnose the patient's disease or condition? If yes, please detail. Note: To be eligible for marketing approval under the HDE regulations, the sponsor must show that no comparable device, other than this device or a device being studied under an IDE, is available.**
Alternatives

10 * **Will data be collected on the patients?**

Yes No

If YES:

10.1 **Will the collection of data be on safety and effectiveness and used to support a pre-marketing (PMA) application?**

Yes No

If YES, this is not the correct form - you will be re-directed to the General Information form where you need to change type of submission to "New Research Activity" as the type of your research.

10.2 **Will data be collected for any type of database or data repository?**

Yes No

If YES:

10.2.1 **Please describe.**

Description of registry

10.2.2 **Describe how the data will be stored, confidentiality maintained and who will have access to the data.**

Protection of data

11 * **Who will cover the cost of the device and any procedures associated with using or implanting the device?**
Cost of device

12 **Attach the following Humanitarian Device Exemption (HDE) documentation as provided by the sponsor.**

12.1 **FDA Humanitarian Device Exemption (HDE) approval letter (or similar form from sponsor)**

Name	Date Last Modified	Version	Owner
HDE approval letter.docx	12/4/2019 2:51 PM	0.01	Ashley Kuniholm

12.2 **HUD manufacturer's information, including product labeling, clinical brochure and any other pertinent manufacture information materials.**

Name	Date Last Modified	Version	Owner
Device label.docx	12/4/2019 2:51 PM	0.01	Ashley Kuniholm

13 * **Explain who will obtain consent, when and how.**
Consent procedures

13.1 Attach the Humanitarian Use Device consent form or information sheet to be provided to patients. Note if data is being collected in a database or repository to be used for future research or future additional marketing initiatives, please be sure the consent includes information regarding those uses.

Your consent must use the current required format. [Click here to download the template.](#)

Name	Date Last Modified	Version	Owner
Consent Form.docx	12/4/2019 2:51 PM	0.01	Ashley Kuniholm

Title: Sample Humanitarian Use Device (HUD)

Additional Documents

1 Please upload any additional documents if it is necessary.

Name	Date Last Modified	Version	Owner
There are no items to display			

PI's Statement

- I assure the information I obtain as part of this research (including protected health information) will not be reused or disclosed to any other person or entity other than those listed on this form, except as required by law or for authorized oversight of the research project. If at any time I want to reuse this information for other purposes or disclose the information to other individuals or entity, I will seek approval by the Institutional Review Board (IRB).
- I assure the IRB that there are appropriate resources (funding, equipment, space, support services) to conduct this research safely and in accordance with all required human subject protection policies.

* The PI accepts responsibility for assuming adherence to DHHS, FDA, HIPAA and Children's Hospital's regulations and policies relative to the protection of the rights and welfare of patients/subjects participating in this study.

Yes No